Molecular typing of renal cancer from genomic changes, DNA methylation profiles, RNA and protein levels has revealed repeated mutations in the PI3K/AKT pathway, suggesting that this pathway is a potential therapeutic target (62). This evidence concerns the gene AKT1 and renal carcinoma.